Alnylam Pharmaceuticals Inc
ALNY251.560USD
+8.949+3.69%
收盘 04/25, 16:00（美东）报价延迟15分钟
32.53B总市值
亏损市盈率 TTM
关于 Alnylam Pharmaceuticals Inc 公司
Alnylam Pharmaceuticals, Inc. 是一家商业阶段的生物制药公司。该公司致力于发现、开发、制造和商业化基于核糖核酸干扰 (RNAi) 的新型疗法。其上市产品包括用于治疗成人遗传性转甲状腺素介导性淀粉样变性 (hATTR) 伴多发性神经病的 AMVUTTRA (vutrisiran)；用于治疗成人 hATTR 淀粉样变性伴多发性神经病的 ONPATTRO (patisiran)；用于治疗成人急性肝卟啉症的 GIVLAARI (givosiran)；用于治疗 1 型原发性高草酸尿症的 OXLUMO (lumasiran)，以及由其合作伙伴诺华公司开发和商业化的 Leqvio (inclisiran)，用于治疗成人高胆固醇血症或混合性血脂异常。该公司的临床开发项目包括 Cemdisiran、Fitusiran、Zilebesiran、Elebsiran、Mivelsiran 和 ALN-HTT02。该公司正在开发 Cemdisiran 来治疗补体介导的疾病。
公司简介
公司代码ALNY
公司名称Alnylam Pharmaceuticals Inc
上市日期May 28, 2004
成立日期2003
CEODr. Yvonne L. Greenstreet, M.D.
员工数量2230
证券类型Ordinary Share
年结日May 28
公司地址675 W Kendall St
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02142-1168
电话16175518200
网址https://www.alnylam.com/
公司代码ALNY
上市日期May 28, 2004
成立日期2003
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Phillip A. (Phil) Sharp, Ph.D.
Dr. Phillip A. (Phil) Sharp, Ph.D.
Independent Director
Independent Director
266.90K
--
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
99.04K
+16.58%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
47.81K
+40.80%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
28.01K
+95.27%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.03K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
3.64K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
136.00
--
Ms. Colleen F. Reitan
Ms. Colleen F. Reitan
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Carolyn R. Bertozzi, M.D.
Ms. Carolyn R. Bertozzi, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Phillip A. (Phil) Sharp, Ph.D.
Dr. Phillip A. (Phil) Sharp, Ph.D.
Independent Director
Independent Director
266.90K
--
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
99.04K
+16.58%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
47.81K
+40.80%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
28.01K
+95.27%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.03K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
3.64K
--
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
业务USD
名称
营收
占比
AMVUTTRA
970.45M
43.16%
Regeneron Pharmaceuticals
302.80M
13.47%
GIVLAARI
255.87M
11.38%
ONPATTRO
252.86M
11.25%
OXLUMO
167.05M
7.43%
Other
299.22M
13.31%
地区USD
名称
营收
占比
United States
933.54M
41.52%
Europe
516.30M
22.96%
Net revenues from collaborations
510.22M
22.69%
Rest of World
196.39M
8.74%
Royalty revenue
91.79M
4.08%
业务
地区
业务USD
名称
营收
占比
AMVUTTRA
970.45M
43.16%
Regeneron Pharmaceuticals
302.80M
13.47%
GIVLAARI
255.87M
11.38%
ONPATTRO
252.86M
11.25%
OXLUMO
167.05M
7.43%
Other
299.22M
13.31%
股东统计
更新时间: 2月21日 周五
更新时间: 2月21日 周五
持股股东
股东类型
持股股东
股东统计
占比
Capital World Investors
12.76%
The Vanguard Group, Inc.
10.04%
Fidelity Management & Research Company LLC
9.95%
Capital Research Global Investors
5.36%
BlackRock Institutional Trust Company, N.A.
5.19%
Other
56.70%
持股股东
股东统计
占比
Capital World Investors
12.76%
The Vanguard Group, Inc.
10.04%
Fidelity Management & Research Company LLC
9.95%
Capital Research Global Investors
5.36%
BlackRock Institutional Trust Company, N.A.
5.19%
Other
56.70%
股东类型
股东统计
占比
Investment Advisor
56.07%
Investment Advisor/Hedge Fund
32.20%
Corporation
3.44%
Hedge Fund
2.58%
Sovereign Wealth Fund
1.97%
Pension Fund
1.43%
Bank and Trust
1.19%
Research Firm
1.07%
Individual Investor
0.43%
机构持股
更新时间: 1月19日 周日
更新时间: 1月19日 周日
报告期
机构数
持股数
持股占比
持股变动
2025Q1
1235
131.13M
100.81%
-458.58K
2024Q4
1263
130.73M
100.99%
-1.47M
2024Q3
1225
126.90M
98.51%
-1.26M
2024Q2
1183
123.30M
96.32%
+1.12M
2024Q1
1172
117.88M
93.23%
-5.46M
2023Q4
1169
120.70M
96.18%
-5.54M
2023Q3
1125
121.55M
96.89%
-6.15M
2023Q2
1119
122.11M
98.30%
-6.32M
2023Q1
1116
123.13M
99.37%
-5.56M
2022Q4
1103
122.98M
99.27%
-3.16M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Capital World Investors
16.60M
12.76%
+92.10K
+0.56%
Dec 31, 2024
The Vanguard Group, Inc.
13.06M
10.04%
+378.83K
+2.99%
Mar 31, 2025
Fidelity Management & Research Company LLC
12.94M
9.95%
-1.20M
-8.49%
Dec 31, 2024
Capital Research Global Investors
6.97M
5.36%
+1.72M
+32.89%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
6.75M
5.19%
+149.81K
+2.27%
Dec 31, 2024
Regeneron Pharmaceuticals Inc
4.44M
3.42%
+4.44M
--
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
4.38M
3.37%
+1.25M
+39.67%
Dec 31, 2024
Wellington Management Company, LLP
4.20M
3.23%
-756.72K
-15.28%
Dec 31, 2024
Baillie Gifford & Co.
4.04M
3.11%
-846.74K
-17.33%
Dec 31, 2024
Dodge & Cox
3.54M
2.72%
-82.27K
-2.27%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
Tema Neuroscience and Mental Health ETF
4.39%
VanEck Biotech ETF
4.19%
Global X Genomics & Biotechnology ETF
3.91%
ProShares Ultra Nasdaq Biotechnology
3.49%
First Trust NYSE Arca Biotechnology Index Fund
3.23%
iShares Biotechnology ETF
3.11%
Invesco Nasdaq Biotechnology ETF
3.05%
Franklin Genomic Advancements ETF
2.56%
American Century Focused Dynamic Growth ETF
2.52%
SPDR S&P Biotech ETF
2.5%
查看更多
Tema Neuroscience and Mental Health ETF
占比4.39%
VanEck Biotech ETF
占比4.19%
Global X Genomics & Biotechnology ETF
占比3.91%
ProShares Ultra Nasdaq Biotechnology
占比3.49%
First Trust NYSE Arca Biotechnology Index Fund
占比3.23%
iShares Biotechnology ETF
占比3.11%
Invesco Nasdaq Biotechnology ETF
占比3.05%
Franklin Genomic Advancements ETF
占比2.56%
American Century Focused Dynamic Growth ETF
占比2.52%
SPDR S&P Biotech ETF
占比2.5%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据